EAM
TGTX icon

Eagle Asset Management’s TG Therapeutics TGTX Stock Holding History

Eagle Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.86M Buy
+168,795
New +$3.69M 0.02% 392
2024
Q2 		– Sell
-87,064
Closed -$1.29M – 596
2024
Q1 		$1.29M Buy
+87,064
New +$1.39M 0.01% 488
2022
Q3 		– Sell
-701,690
Closed -$2.98M – 577
2022
Q2 		$2.98M Buy
701,690
+226,500
+48% +$1.41M 0.02% 413
2022
Q1 		$4.52M Buy
475,190
+22,837
+5% +$264K 0.02% 391
2021
Q4 		$8.75M Sell
452,353
-5,793
-1% -$150K 0.04% 329
2021
Q3 		$15.2M Sell
458,146
-381,108
-45% -$11.8M 0.07% 245
2021
Q2 		$32.6M Buy
839,254
+7,707
+0.9% +$303K 0.14% 192
2021
Q1 		$40.7M Sell
831,547
-524,305
-39% -$25.2M 0.18% 176
2020
Q4 		$70.5M Sell
1,355,852
-122,877
-8% -$4.15M 0.4% 87
2020
Q3 		$38.7M Buy
1,478,729
+33,677
+2% +$775K 0.2% 173
2020
Q2 		$26.8M Buy
+1,445,052
New +$23.3M 0.15% 188

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eagle Asset Management's TGTX Position: Q3 2024 in Review

Eagle Asset Management opened a new position in TG Therapeutics (TGTX) in Q3 2024: 168,795 shares worth $4.86M. The stake represents 0.02% of the portfolio and ranks #392 among its holdings. This is a return to the name: Eagle Asset Management previously reported a position in TGTX as recently as Q1 2024.

Eagle Asset Management first reported a position in TGTX in Q2 2020 and has held it in 11 quarters since. The position peaked at $70.5M in Q4 2020. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Eagle Asset Management held 168,795 shares of TG Therapeutics worth $4.86M as of Q3 2024.
  • TG Therapeutics was a new Eagle Asset Management position in Q3 2024.
  • TG Therapeutics made up 0.02% of Eagle Asset Management's portfolio in Q3 2024, its #392 holding.
  • Eagle Asset Management first reported a position in TG Therapeutics in Q2 2020 and has held it in 11 quarters since.
  • Eagle Asset Management's TG Therapeutics position peaked at $70.5M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.